PaulJOrchardMD

Pediatric Hematology & Oncology • Minneapolis, MN

Paul J. Orchard, MD Professor, Division of Pediatric Bone Marrow Transplantation University of Minnesota

Join to view full profile

Dr. Orchard is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Orchard's full profile

Already have an account?

Office
660B, Masonic Cancer Research Center
425 E River Parkway
Minneapolis, MN 55455
Phone+1 612-626-2313

Education & Training

University of MinnesotaFellowship, Pediatric Hematology/Oncology, 1987 - 1990
University of Wisconsin Hospitals and ClinicsResidency, Pediatrics, 1984 - 1987
The Warren Alpert Medical School of Brown UniversityClass of 1984

Certifications & Licensure

MN State Medical License 1988 - 2025
WI State Medical License 1985 - 1987

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014-2019
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com

Clinical Trials

Stem Cell Transplant for Bone Marrow Failure Syndromes Start of enrollment: 2000 Jun 01
Completed
Phase 2, Phase 3
Stem Cell Transplant w/Laronidase for Hurler Start of enrollment: 2004 Mar 01
Completed
Phase 2
Stem Cell Transplant for Inborn Errors of Metabolism Start of enrollment: 1995 Jan 01
Completed
Phase 2, Phase 3
Stem Cell Transplantation for Hurler Start of enrollment: 1999 May 01
Completed
Phase 2
HSCT for High Risk Inherited Inborn Errors Start of enrollment: 2006 Sep 01
Completed
Phase 2
Intrathecal Enzyme Replacement for Hurler Syndrome Start of enrollment: 2008 Jan 02
Completed
Phase 1
Reduced Intensity AlloTransplant For Osteopetrosis Start of enrollment: 2007 Sep 01
Terminated
Phase 2
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism Start of enrollment: 2008 Mar 01
Terminated
Phase 2
Allogeneic Transplantation For Severe Osteopetrosis Start of enrollment: 2008 Aug 01
Completed
Phase 2, Phase 3
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders Start of enrollment: 2009 Dec 01
Completed
Phase 2
Administration of IV Laronidase Post Bone Marrow Transplant in Hurler Start of enrollment: 2012 May 29
Completed
Phase 1
Laronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler Syndrome Start of enrollment: 2012 Mar 28
Terminated
A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD) Start of enrollment: 2013 Aug 21
Completed
Phase 2, Phase 3
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis Start of enrollment: 2014 Jul 10
Recruiting
Phase 2
Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies Start of enrollment: 2014 Sep 02
Recruiting
Not Applicable
Early Diagnosis Of Childhood Cerebral ALD Start of enrollment: 2018 Nov 01
Withdrawn
Adrenoleukodystrophy National Registry Study Start of enrollment: 2019 May 01
Recruiting
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC) Start of enrollment: 2012 Aug 01
Recruiting
Not Applicable
Roles: Contact
MT2018-18: Sleeping Beauty Transposon-Engineered Plasmablasts for Hurler Syndrome Post Allo HSCT Start of enrollment: 2022 Dec 01
Withdrawn
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Prevalence and natural history of gibbus deformity in patients with Hurler syndrome.
Shiwei Huang, Troy Lund, Paul Orchard, Ashish Gupta, David Nascene
Neuroradiology. 2024-11-01
A Novel Mouse Model for Cerebral Inflammatory Demyelination in X-Linked Adrenoleukodystrophy: Insights into Pathogenesis and Potential Therapeutic Targets.
Ezzat Hashemi, Isha N Srivastava, Alejandro Aguirre, Ezra T Yoseph, Esha Kaushal
Annals of Neurology. 2024-10-28
1 citations
Secondary failure of lentiviral vector gene therapy in a cerebral adrenoleukodystrophy patient with an ABCD1 whole-gene deletion.
Troy C Lund, Paul J Orchard, David R Nascene, Carina J King, Jennifer Braun
Molecular Therapy. 2024-10-02

Journal Articles

Successful Hematopoietic Cell Transplantation Following Cardiac Transplantation in Two Pediatric Patients
Paul J Orchard, Angela R Smith, Rachel Phelan, Rebecca K Ameduri, Pediatric Transplantation

Press Mentions

Eli-Cel from Bluebird Gets Accelerated Approval for Boys with CALDSeptember 19th, 2022
Bluebird Bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)September 16th, 2022
Seattle Biotech Company Is the First to Receive Approval to Test B Cell Gene Therapy in HumansSeptember 1st, 2022
Join now to see all

Grant Support

Clinical Trial: Phase II Study Of Combined Laronidase (ALDURAZYME) Enzyme ReplacNational Center For Research Resources2008–2009
Phase II Study Of Combined Laronidase (ALDURAZYME) Enzyme Replacement Therapy (ENational Center For Research Resources2006–2007
Transplantation Of URB T Cells Containing The HSV-TK Suicide GeneNational Center For Research Resources2004–2006
First International Symposium On Osteopetrosis:National Institute Of Arthritis And Musculoskeletal And Skin Diseases2003